Is Cardiogen FDA approved?
No. This profile records Cardiogen as not FDA approved and for research use only.
MORE CONTEXT ›
Review the regulatory and source details on this page for the current context.
THE CARDIAC REGENERATOR
AEDR tetrapeptide; H-Ala-Glu-Asp-Arg-OH
Cardiogen is a synthetic tetrapeptide (AEDR) from the Khavinson family designed to support heart health. It stimulates cardiac progenitor cells to repair damaged heart tissue, reduces scarring after heart attacks, and may even have tumor-inhibiting properties. It's being studied for myocardial recovery and anti-aging.
Not FDA approved · research use only
Reviewed by our clinical team
1 research sources
May 8, 2026
Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.
No. This profile records Cardiogen as not FDA approved and for research use only.
Review the regulatory and source details on this page for the current context.
Dose: 2 mg daily for 2 weeks (subcutaneous).
Schedule: daily. Cycle: 2 weeks on, 12 weeks off. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.
This guide links to 1 curated or current research sources.
Open the research section to inspect the source titles, publication details, study types, and available abstracts directly.
Stimulates heart progenitor cells to regenerate damaged tissue
Reduces scar tissue formation in the heart
Protects heart cells from programmed death
The live research feed did not return papers for this page. The curated references below remain available for crawlable source context.